AI Health Platform

Invest in the Future of Digital Health

Welcome to DrVitos — a next-generation health platform revolutionizing obesity treatment through advanced telemedicine, AI-powered tools, and strategic partnerships. With a focus on accessibility, personalization, and prevention, DrVitos connects patients with licensed physicians for seamless care, from diagnosis to prescriptions and long-term support.

By combining digital innovation with medical expertise, DrVitos empowers individuals to take control of their health—anywhere, anytime.

Why Invest in DrVitos?

Massive Market Need: Over 50% of adults in Europe are overweight or obese, creating a healthcare burden exceeding €30 billion annually in direct and indirect costs.
Fast-Growing Market: The global obesity therapeutics market is projected to grow from $14.8B in 2024 to $77.2B by 2030 (CAGR: 31.66%).
Proven Demand: Patients are actively seeking digital, doctor-led platforms for Ozempic (GLP-1) prescriptions—DrVitos is uniquely positioned to meet this demand.
Subscription Model: DrVitos combines consultation, prescription, and monitoring into a recurring revenue model with strong customer lifetime value.
Fair Valuation: Estimated at ~€9.400.000 by independent valuation (TPPR, April 2025).

The DrVitos Process

1

Digital Self-Assessment

Patients visit drvitos.com to perform an easy online health evaluation.
2

Medical Review & Recommendations

Licensed doctors analyze results and offer tailored treatment plans, including GLP-1 prescriptions and wellness products.
3

Optional Lab Diagnostics

In partnership with LifeComp Analytics and Synlab, patients can access advanced blood testing and physical health checks.
4

Ongoing Support

Subscription-based follow-ups include real-time AI feedback, lifestyle recommendations, and regular physician reviews.

The Business Model

Revenue Streams:

Consultation Fees: €90 / SEK 945 per session
Subscription: €85 / SEK 890 per quarter for long-term care
Prescription Fees: In partnership with licensed pharmacies
Affiliate Income: From partner brands in health and wellness

2027 Revenue Target: €50.000.000

EBITDA Positive: Projected from Year 1

Market Expansion Strategy

Active Markets: Sweden, Norway, United Kingdom

2026 Expansion: Germany, France, Netherlands

2027 Goals: Southern & Eastern Europe

Initial customer base: 10,000 in 2026

Growth target: 250,000 patients by 2028

Focus: GLP-1 prescriptions, diagnostics, and digital therapeutics

Strategic Partnerships

LifeComp Analytics: Health tech partner for diagnostics and data-driven wellness plans
Dr. Afshin Motamedi Clinic (Stockholm): In-person care extension in Sweden
Corporate Clinic Acquisition (Kungsholmen): Access to 500+ SME clients, 37,000 individuals

These collaborations combine physical infrastructure with digital scale—driving profitability and patient trust.

Platform Strengths

AI-based health guidance tools (launching 2025)

Fully licensed platform with Swedish IVO compliance

Seamless integration with pharmacies and labs

Multilingual medical team across regions

Investment Overview

Feature	Details
Investment Entity	Nomirag AB (Sweden) — to be public-listed
Target Round	SEK 15M
Valuation	SEK 80M pre-money
Equity Offered	~15.79%
Minimum Investment	€5000
Offer Timeline	June 2025 - August 2025
Exit Strategy	Planned IPO on major European stock market

Use of Funds

Why Now?

Demand for GLP-1-based obesity treatment is exploding—patients want digital access, doctors want scalable tools, and markets want innovation. DrVitos is already in motion with real patients, strong tech, and a roadmap to dominate a high-growth vertical in European healthtech.

Invest early. Shape the future of healthcare.

Invest in a Revolution. Invest in DrVitos.

Join us in shaping the future of healthcare—where technology, security, and innovation meet unparalleled simplicity and impact. Go to DrVitos

Let’s Build a Healthier Future Together.

Investor Presentation

Business Plan

Executive Summary

Valuation Report